Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11901
Marine Petroleum Trust
MARPS
$9.84M
| $44.3K | ﹤0.01% |
+11,398
| New | +$45.9K |
|
11902
Globus Maritime Ltd
GLBS
$81.6M
| $43.8K | ﹤0.01% |
36,176
-23,459
| -39% | -$30.5K |
|
|
AIFA
11903
All In FutureTech Alliance Inc
AIFA
$19M
| $43.7K | ﹤0.01% |
7,145
-607
| -8% | -$3.74K |
|
11904
Solitario Resources
XPL
$76.6M
| $43.3K | ﹤0.01% |
72,086
-101,517
| -58% | -$66.6K |
|
11905
CALL
Veru
VERU
$47.1M
| $43.2K | ﹤0.01% |
8,820
-13,810
| -61% | -$85.6K |
|
11906
Karyopharm Therapeutics
KPTI
$42.9M
| $43.2K | ﹤0.01% |
11,548
-32,728
| -74% | -$279K |
|
11907
Zedge
ZDGE
$38.3M
| $43.2K | ﹤0.01% |
18,528
-6,414
| -26% | -$16.3K |
|
|
AGEN
11908
Agenus
AGEN
$365M
| $43K | ﹤0.01% |
28,581
-100,581
| -78% | -$290K |
|
|
BTOC
11909
Armlogi Holding Corp
BTOC
$13.2M
| $42.9K | ﹤0.01% |
+42,935
| New | +$122K |
|
11910
CALL
Annexon
ANNX
$954M
| $42.8K | ﹤0.01% |
22,200
-108,000
| -83% | -$359K |
|
11911
PUT
Lexeo Therapeutics
LXEO
$411M
| $42.7K | ﹤0.01% |
+12,300
| New | +$54.5K |
|
|
GAN
11912
DELISTED
GAN Ltd
GAN
| $42.5K | ﹤0.01% |
24,009
-27,556
| -53% | -$49.7K |
|
11913
PUT
Prime Medicine
PRME
$635M
| $42.4K | ﹤0.01% |
21,300
-5,100
| -19% | -$13K |
|
|
XXII
11914
22nd Century Group
XXII
$2.28M
| $42.2K | ﹤0.01% |
+4
| New | +$95.2K |
|
11915
CVD Equipment Corp
CVV
$51.6M
| $42K | ﹤0.01% |
+13,684
| New | +$47K |
|
|
LITS
11916
Lite Strategy Inc
LITS
$33.8M
| $41.8K | ﹤0.01% |
19,095
-3,531
| -16% | -$9.17K |
|
|
MTA
11917
PUT
Metalla Royalty & Streaming
MTA
$1.03B
| $41.8K | ﹤0.01% |
14,600
-17,800
| -55% | -$51.5K |
|
|
MASK
11918
3 E Network Technology Group
MASK
$4.53M
| $41.7K | ﹤0.01% |
+448
| New | +$33K |
|
11919
Ebang International Holdings
EBON
$14.2M
| $41.3K | ﹤0.01% |
+10,610
| New | +$55.3K |
|
11920
CALL
Annovis Bio
ANVS
$75.4M
| $41.3K | ﹤0.01% |
27,500
-293,200
| -91% | -$897K |
|
|
11921
PUT
Karyopharm Therapeutics
KPTI
$42.9M
| $41.1K | ﹤0.01% |
11,000
+9,420
| +596% | +$80.4K |
|
11922
PUT
Microbot Medical
MBOT
$99.4M
| $41.1K | ﹤0.01% |
+27,200
| New | +$48.1K |
|
|
FLNT
11923
Fluent
FLNT
$126M
| $41K | ﹤0.01% |
18,798
-6,348
| -25% | -$16.8K |
|
11924
Nephros
NEPH
$46.6M
| $40.6K | ﹤0.01% |
23,618
-184
| -0.8% | -$289 |
|
11925
Armata Pharmaceuticals
ARMP
$202M
| $40.4K | ﹤0.01% |
27,681
-22,107
| -44% | -$44K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.